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Background: ECMO is an established supportive adjunct for patients with severe, refractory ARDS from
viral pneumonia. However, the exact role and timing of ECMO for COVID-19 patients remains unclear.
Methods: We conducted a retrospective comparison of the first 32 patients with COVID-19-associated
ARDS to the last 28 patients with influenza-associated ARDS placed on V-V ECMO. We compared pa-
tient factors between the two cohorts and used survival analysis to compare the hazard of mortality over
sixty days post-cannulation.
Results: COVID-19 patients were older (mean 47.8 vs. 41.2 years, p ¼ 0.033), had more ventilator days
before cannulation (mean 4.5 vs. 1.5 days, p < 0.001). Crude in-hospital mortality was significantly higher
in the COVID-19 cohort at 65.6% (n ¼ 21/32) versus 36.3% (n ¼ 11/28, p ¼ 0.041). The adjusted hazard
ratio over sixty days for COVID-19 patients was 2.81 (95% CI 1.07, 7.35) after adjusting for age, race,
ECMO-associated organ failure, and Charlson Comorbidity Index.
Conclusion: ECMO has a role in severe ARDS associated with COVID-19 but providers should carefully
weigh patient factors when utilizing this scarce resource in favor of influenza pneumonia.
© 2021 Elsevier Inc. All rights reserved.Introduction
Veno-venous extracorporeal membrane oxygenation (V-V
ECMO) is an established supportive adjunct in managing patients
with severe acute respiratory distress syndrome (ARDS) unre-
sponsive to conventional and maximal ventilatory strategies.1e5
Clinical outcomes following V-V ECMO for specific respiratory pa-
thologies (such as viral pneumonia, aspiration pneumonitis,
trauma, etc.) and the optimal timing for initiation of ECMO in the
critically ill has been well described.6e8 The best reported clinical
outcomes for ECMO are associatedwith younger age, fewermedical
comorbidities, and less than seven ventilator days before
cannulation.9
The 2009 H1N1 influenza pandemic was a catalyst for the
increasing use of V-V ECMO in ARDS.10 The reported mortality forilding, CB# 7228, Chapel Hill,
Gallaher).
D. Johnson et al., Comparative
on for severe ARDS, The Amerall critically ill patients with influenza pneumonia is variable and
reported to be between 8 and 50%, depending on the patient
population, hospital resources, severity of illness, and the viral
strain.11e13 In contrast, several studies have reported an in-hospital
mortality as low as 8e21% for patients with H1N1 influenza-
associated severe ARDS managed with ECMO, suggesting that
ECMO may impart a greater survival benefit in patients with H1N1
influenza infection.6e8
Unfortunately, ECMO providers are now facing their second
pandemic in a decade with COVID-19, where clinical outcomes for
critically ill patients are even worse, with early results from China
reporting a mortality as high as 60%.14 Initial reports from China on
the use of V-V ECMO in COVID-19 demonstrated a mortality as high
as 83%, although the studies were small, limiting the ability to draw
definitive conclusions.14,15 Recent data from the Extracorporeal Life
Support Organization (ELSO) registry reports in-hospital mortality
for all COVID-19 patients treated with ECMO at less than 40%.16
Unfortunately, the ideal candidate for ECMO and the optimal
timing for cannulation in COVID-19 positive patients with severe
ARDS is not yet well characterized. This may be attributable, in part,outcomes between COVID-19 and influenza patients placed on veno-
ican Journal of Surgery, https://doi.org/10.1016/j.amjsurg.2021.04.004
L.A. Raff, T.D. Reid, D. Johnson et al. The American Journal of Surgery xxx (xxxx) xxxto the older population affected by COVID-19, the associated coa-
gulopathy and other systemic complications observed in COVID-19,
and the higher incidence of concomitant severe medical comor-
bidities in the critically ill COVID-19 patient cohort.17
Currently, there are very little data comparing the clinical
characteristics and outcomes of critically ill patients with severe
ARDS secondary to COVID-19 to patients with severe ARDS sec-
ondary to influenza, with even fewer data comparing the use of V-V
ECMO for severe ARDS in these two populations.18e21 This up-
coming winter may compel ECMO providers to triage patients with
severe ARDS that will likely benefit from V-V ECMO, given the
confluence of increased influenza prevalence amidst the current
COVID-19 surge across the United States and Europe. Consequently,
we sought to compare our institutional experience between
COVID-19 and influenza patients with severe ARDS placed on V-V
ECMO, highlighting essential differences in patient characteristics
and clinical outcomes.
Materials and methods
We performed a retrospective study comparing patient char-
acteristics and outcomes in patients with severe ARDS secondary to
polymerase chain reaction (PCR) confirmed influenza versus
reverse-transcriptase polymerase chain reaction (RT-PCR)
confirmed COVID-19 infection managed with V-V ECMO at the
University of North Carolina Medical Center at Chapel Hill
(UNCMC).
UNCMC is a 900-bed quaternary academic medical center with a
high-volume ECMO program caring for neonatal, pediatric, and
adult patients with cardiac and respiratory failure with an average
of 60 adult cannulations each year. The ECMO team consults on
patients in the medical intensive care unit (MICU) with severe
ARDS and evidence of refractory hypoxia or hypercarbia. If the
ECMO provider assesses that the patient is a suitable candidate for
ECMO, an ECMO attending (surgical critical care surgeon) cannu-
lates the patient, and the ECMO team subsequently assumes pri-
mary care of the patient.
We compared the first 32 adult COVID-19 patients with severe
ARDS placed on V-V ECMOwith the last 28 adult influenza patients
with severe ARDS placed on V-V ECMO. All COVID-19 patients were
cannulated between March 2020 and September 2020 while
influenza patients were cannulated between November 2013 and
March 2020. Per protocol, all cannulated patients were placed on
rest ventilatory settings to decrease ventilator-associated lung
injury (pressure control of 20 cm H2O, rate of 10 breaths per
minute, positive end-expiratory pressure of 10 cm H2O, fraction of
inspired oxygen of 40%). The ECMO team then monitored tidal
volumes to track improvement in pulmonary compliance over time.
All patients in both groups were therapeutically anticoagulated
while on ECMO with the same protocol.
Collected variables from the review of the medical records
include patient demographics, medical comorbidities, vital signs,
and the date of the first positive PCR test or RT-PCR test for influ-
enza and SARS-CoV-2, respectively. We also collected time-
dependent variables such as the duration of symptoms, duration
of use of non-invasive positive pressure ventilation (NIPPV),
ventilator days, and days on ECMO. In addition, we collected data
on the presence of barotrauma at the time of ECMO cannulation
(defined as pneumothorax, pneumomediastinum, or subcutaneous
emphysema on chest x-ray imaging not from another cause), pre-
cannulation arterial blood gas values, PaO2/FIO2 (P/F) ratio, and
ventilator settings, the Murray score, and the use of prone posi-
tioning and paralytics before cannulation.
The primary outcome was survival to hospital discharge. Sec-
ondary outcomes included ECMO related complications such as2
bleeding events, air emergencies, and organ failure (liver, kidney,
cardiac). We defined minor hemorrhagic complications as bleeding
episodes managed at the bedside from mucosal surfaces, around
the cannula or other lines, gastrointestinal bleeding that did not
require intervention, or Foley catheter-associated bleeding. We
defined major hemorrhagic complications as bleeding episodes
requiring interventional radiology, endoscopy, operative explora-
tion, E-aminocaproic acid infusion, or initiation of massive trans-
fusion protocol.
We examined the cohort characteristics by assessing the dis-
tribution of variables between COVID-19 patients and influenza
patients. We examined categorical and continuous variables by
calculating the frequencies of categorical variables and the distri-
bution of continuous variables. We used bivariate analysis to
compare variables across the study cohorts and identify potential
confounders of the relationship between the viral etiology of ARDS
and mortality. We used Pearson’s correlation for the categorical
variables and 2-sample t-tests or one-way analysis of variance for
continuous variables. Medians of non-normally distributed
continuous variables were tested using a Kruskal-Wallis test. We
reported means with standard deviations (SD) and medians with
interquartile ranges (IQR).
We utilized survival analysis to estimate the hazard ratio for in-
hospital mortality through sixty days for ECMO patients with
COVID-19 infection compared to influenza infection. We initially
plotted an unadjusted Kaplan-Meier curve comparing the two co-
horts and utilized a Cox proportional regression model to estimate
the unadjusted mortality hazard ratio for patients with COVID-19
infection. We then repeated the Cox proportional regression
model adjusting for potential confounders. A potential confounder
was included in the model if it substantially affected the adjusted
hazard ratio. Among potential confounders, we assessed and cor-
rected for violation of the proportional hazard assumption. The
model used 60-days as the time frame to capture all deaths in the
cohorts and account for ECMO duration. An adjusted hazard ratio
for patients with COVID-19 infection and 95% confidence interval
compared to those with influenza infection are reported. In addi-
tion, Kaplan-Meier curve adjusting for the same potential con-
founders is reported.
The University of North Carolina Institutional Review Board
approved this study, and the need for consent was waived. We used
Stata/SE 16.1 (Stata- Corp LP, College Station, TX) for all statistical
analysis.
Results
Overall, we included 32 patients with confirmed COVID-19 and
28 patients with confirmed influenza pneumonia in the analysis.
Table 1 summarizes patient characteristics, including demographic
data and clinical indicators at the time of cannulation. Notably,
COVID-19 patients were significantly older, with a mean age of 47.8
years (SD 10.3) compared to 41.2 years (SD 12.8, p ¼ 0.033) among
influenza patients. There was a male preponderance with a similar
BMI between the two cohorts. There were significantly more His-
panic patients in the COVID-19 group at 53.1% (n¼ 17) compared to
7.1% (n ¼ 2, p < 0.001), and fewer Caucasians among COVID-19
patients at 28.1% (n ¼ 9) compared to 64.3% (n ¼ 18). The median
Charlson Comorbidity Index (CCI) was similar in both groups (1 in
COVID-19 versus 0 in influenza, p ¼ 0.4), but the prevalence of
diabetes was muchmore common among COVID-19 patients, 50.0%
(n ¼ 16) versus 10.7% (n ¼ 3, p ¼ 0.001) in the influenza cohort.
COVID-19 patients had a significantly longer duration of symp-
toms before ECMO cannulation than influenza patients with a
mean of 16.2 days (SD 8.3) compared to 8.5 days (SD 4.4, p < 0.001)
(Table 1). Also, COVID-19 patients had a longer ICU admission
Table 1
A comparison of patient factors between those who were placed on VV ECMO for ARDS secondary to COVID-19 infection versus those with ARDS secondary to confirmed
influenza infection.
Patients with COVID-19 (n ¼ 32) Patients with Influenza (n ¼ 28) p value
Patient Factors
Age (years)
Mean (SD) 47.8 (10.3) 41.2 (12.8) 0.033
Sex: n (%)
Male 25 (78.1) 16 (57.1) 0.08
Female 7 (21.9) 12 (42.9)
BMI
Mean (SD) 35.1 (7.8) 37.1 (10.1) 0.4
Race: n (%)
Latino 17 (53.1) 2 (7.1) <0.001
African-American 6 (18.8) 5 (17.9)
Caucasian 9 (28.1) 18 (64.3)
Other 0 (0.0) 3 (10.7)
Diabetic?
Yes: n (%) 16 (50.0) 3 (10.7) 0.001
Charleson Comorbidity Index:
Median (IQR) 1 (0e2) 0 (0e1.5) 0.4
Clinical Status
Number of Days from Symptom Onset to Cannulation
Mean (SD) 16.2 (8.3) 8.5 (4.4) <0.001
Use of Non-invasive Positive-Pressure (NIPPV) Ventilation Prior to Cannulation
Yes: n (%) 25 (78.1) 14 (50.0) 0.023
Mean Days on Non-Invasive Ventilation: Mean (SD) 3.3 (4.1) 0.78 (1.8) 0.004
Proned Prior to Cannulation?
Yes: n (%) 26 (81.3) 1 (3.6) <0.001
Number of Days from ICU Admission to Cannulation
Mean (SD) 8.7 (7.2) 1.8 (2.2) <0.001
Number of Days of Intubation Prior to Cannulation
Mean Days (SD) 4.5 (4.3) 1.5 (1.7) <0.001
P:F Ratio at Cannulation
Mean (SD) 69.3 (19.9) 58.5 (33.8) 0.1
Murray Score at Cannulation
Score 0 0 (0.0) 0 (0.0) 1.0
Score 0.1e2.5 0 (0.0) 0 (0.0)
Score > 2.5 32 (100.0) 32 (100.0)
Labs at Cannulation:
Mean (SD)
Serum pH 7.31 (0.11) 7.23 (0.12) 0.006
Fibrinogen 695 (249) 419 (207) <0.001
D-dimer 3628 (5277) 3503 (5287) 0.9
L.A. Raff, T.D. Reid, D. Johnson et al. The American Journal of Surgery xxx (xxxx) xxxbefore cannulation at 8.7 days (SD 7.2) versus 1.8 days (SD 2.2,
p < 0.001). The use of non-invasive positive-pressure ventilation
(NIPPV) was common in both groups at 78.1% (n ¼ 25) among
COVID-19 patients and 50% (n ¼ 14, p ¼ 0.023) among influenza
patients. However, the use of prone positioning was much more
common in COVID-19 patients at 81.3% (n ¼ 26) versus only 3.6%
(n ¼ 1, p < 0.001) of influenza patients. The average number of
ventilator-days before cannulation was 4.5 days (SD 4.3) among
COVID-19 patients and 1.5 days (SD 1.7, p < 0.001) for influenza
patients. The mean Murray Score in both cohorts was 2.5 at the
time of cannulation with a mean P:F ratio of 69.3 (SD 19.9) among
COVID-19 patients and 58.5 (SD 33.8, p ¼ 0.1) among influenza
patients, consistent with severe ARDS in both groups. D-dimer
levels at cannulation were equally high in both groups, but fibrin-
ogen levels were higher in the COVID-19 group, and pH was lower
in the influenza group (Table 1).
There was a significant difference in V-V ECMO duration be-
tween COVID-19 and influenza patients with a mean of 12.4 days
(SD 5.7) compared to 7.7 days (SD 5.1, p ¼ 0.002), respectively.
(Table 2) COVID-19 patients were more likely to require a circuit
change due to oxygenator failure, with 46.9% (n ¼ 15) of COVID-19
patients requiring circuit change versus 21.4% (n ¼ 6, p ¼ 0.039)
among influenza patients. All oxygenator failures were caused by
micro-thrombi in the circuit. There was a statistically significant
difference in the incidence of organ failurewhile on ECMO between3
the two cohorts. 43.8% (n ¼ 14) of COVID-19 patients developed
organ failure while cannulated and 31.3% (n ¼ 10) required
continuous renal replacement therapy (CRRT). In contrast, 71.4%
(n ¼ 20, p ¼ 0.024) of influenza patients developed organ failure
with 67.9% (n ¼ 19, p ¼ 0.005) requiring CRRT. Minor bleeding
complications occurred frequently for both cohorts at 68.8%
(n ¼ 22) among COVID-19 patients and 67.9% (n ¼ 19, p ¼ 0.9) in
influenza patients. Major bleeding episodes were similar between
the two groups with three (9.4%) major bleeding episodes among
COVID-19 patients and four among influenza patients (14.3%,
p ¼ 0.5).
Overall crude 60-day in-hospital mortality was 53.3% (n ¼ 32/
60) for all patients. We performed a bivariate analysis to assess for
factors associated with mortality across both cohorts, summarized
in Table 3. There was a significant difference in the age of survivors
versus non-survivors, with a mean age of 38.6 years (SD 11.2) in
survivors and 50.1 years (SD 9.7, p < 0.001) in non-survivors. Sex,
BMI, and race were not significantly associated with mortality on
bivariate analysis. CCI was slightly higher among those who died
but was still low with a median of only 1 (IQR 0e2.5, p ¼ 0.002).
There was no significant difference in pre-ECMO ventilator days or
days on NIPPV before intubation nor the pre-cannulation P:F ratio
between survivors and non-survivors. Themean number of days on
ECMO in survivors and non-survivors were 7.3 days (3.2) and 12.8
days (SD 6.6, p < 0.001), respectively.
Table 2
A comparison of circuit outcomes for patients who were placed on VV ECMO for ARDS, stratified by COVID-19 infection versus influenza infection.
Patients Infected with COVID-19 (n ¼ 32) Patients
Infected with Influenza (n ¼ 28)
p value
Number of Days on Circuit
Mean (SD) 12.4 (5.7) 7.7 (5.1) 0.002
ECMO Circuit Changes Required for Oxygenator Failure
Required Change: n (%) 15 (46.9) 6 (21.4) 0.039
Required > 1 circuit change: n (%) 5 (15.6) 2 (7.1) 0.1
Developed Organ Failure on Circuit
Yes: n (%) 14 (43.8) 20 (71.4) 0.031
Placed on CRRT for Renal Failure: n (%) 10 (31.3) 19 (67.9) 0.005
Air Emergency While on Circuit
Yes: n (%) 4 (12.5) 1 (3.6) 0.2
Bleeding Complications on Circuit
Minor: n (%) 22 (68.8) 19 (67.9) 0.9
Major: n (%) 3 (9.4) 4 (14.3) 0.5
Table 3








Mean (SD) 38.6 (11.2) 50.1 (9.7) <0.001
Sex: n (%)
Male 17 (60.7) 24 (75.0) 0.2
Female 11 (39.3) 8 (25.0)
BMI
Mean (SD) 37.5 (10.0) 34.8 (7.8) 0.2
Race: n (%)
Latino 10 (35.7) 9 (28.1) 0.1
African-American 8 (28.6) 3 (9.4)
Caucasian 9 (32.1) 18 (56.3)
Other 1 (3.6) 2 (6.3)
Charleson Comorbidity Index:
Median (IQR) 0 (0e1) 1 (0e2.5) 0.002
Clinical Status
Number of Days of Intubation Prior to Cannulation
Mean Days (SD) 2.2 (3.2) 3.9 (3.8) 0.08
Number of Days of Non-Invasive Positive Pressure Ventilation þ Intubation Prior to Cannulation
Mean Days (SD) 5.4 (9.1) 9.1 (8.5) 0.1
Number of Days on ECMO Circuit
Mean (SD) 7.3 (3.2) 12.8 (6.6) <0.001
P:F Ratio at Cannulation
Mean (SD) 67.0 (34.2) 61.7 (21.5) 0.5
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COVID-19 cohort at 65.6% (n ¼ 21/32) compared to 36.3% (n ¼ 11/
28, p ¼ 0.041) for the influenza cohort. We also conducted a sur-
vival analysis comparing in-hospital mortality between COVID-19
and influenza patients. Upon Cox regression modeling, the unad-
justed hazard ratio over sixty days for COVID-19 patients compared
to influenza patients was 1.87 (95% CI 0.90, 3.91). After fitting the
model with potential confounders, the adjusted hazard ratio over
sixty days for COVID-19 patients compared to influenza patients
was 2.81 (95% CI 1.07, 7.35) after controlling for age, race, organ
failure while on ECMO, and CCI. Fig. 1.
Discussion
To our knowledge, this is one of the first comparisons of patients
treated with V-V ECMO for severe ARDS secondary to COVID-19
versus influenza pneumonia in the United States. Our study dem-
onstrates that COVID-19 patients were older, had a longer time to
cannulation from symptom onset and ICU admission, and required
ECMO for a more extended period of time. Ultimately, COVID-19
patients had an almost threefold increased hazard of in-hospital4
death either during or after ECMO management after adjusting
for confounding variables.
The increased mortality for COVID-19 patients raises critical
questions about the differences in pathophysiology between severe
COVID-19 and severe influenza infection. The descriptions of the
contrasts in clinical presentation between the two viruses in the
literature are consistent with findings from our study.18,22 The older
age seen in critically ill COVID-19 patients compared to influenza
patients may explain some of the differences in mortality between
the two cohorts. Previous data confirm age as a significant risk
factor for death after V-V ECMO for respiratory illnesses. Previous
studies have also linked associated comorbidities such as obesity
and diabetes to critical illness in COVID-19. Our study found that
the incidence of diabetes was higher in COVID-19 with a similar
BMI between the two groups, however neither factor had a
meaningful correlation with mortality.23 This suggests that obesity
is an independent risk factor for the development of severe illness
in all types of viral pneumonia, not just COVID-19, but its rela-
tionship to overall survival needs to be further delineated.24
Despite some of these demographic differences, COVID-19 and
influenza patients had similar markers of severe disease. All
Fig. 1. Adjusted Kaplan-Meier curve comparing patients placed on V-V ECMO with severe COVID-19 infection to patients with severe influenza infection over sixty-days post-
cannulation.
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and Murray Scores, demonstrating that the two cohorts were
similarly critically ill at the time of ECMO cannulation. However,
COVID-19 patients had a significantly longer illness prior to can-
nulation and a longer ECMO course. While the natural history of
severe influenza infection is well established, the clinical course of
COVID-19 is not fully understood.
Other comparison studies between these two viral etiologies
have found a slower disease progression and a longer duration of
critical illness with COVID-19 compared to influenza. These are
known factors that could impact the timing of cannulation, dura-
tion of ECMO therapy, and the ultimate clinical outcome.19,21
Additionally, ECMO may be preferentially delayed for COVID-19
patients as compared to influenza patients, given the frequent
use of NIPPV to avoid mechanical ventilation and the extensive use
of prone positioning for COVID-19 patients, as demonstrated in our
data. Though these treatments may help some patients avoid more
invasive therapies, it may also harm a subset of COVID-19 patients
who may benefit from early ECMO cannulation. Earlier cannulation
may help reduce toxic levels of oxygen or high peak inspiratory
pressures from prolonged NIPPV or mechanical ventilation,
potentially preventing additional lung damage from barotrauma
and ventilator-induced lung injury.25
While factors such as demographic differences and delays to
cannulation may contribute to the increased mortality identified
among COVID-19 patients, we adjusted for these variables in our
survival analysis. Despite this adjustment, COVID-19 still conferred
amuch higher hazard risk of death over sixty days after cannulation
when compared to influenza, suggesting that severe ARDS from
COVID-19 is unique. While the exact pathogenesis of COVID-19
remains unclear, speculation has focused on differences in alve-
olar damage due to inflammation and the higher incidence of
microscopic thrombosis in COVID-19 as compared to other viral
infections.26,27 The number of circuit changes required by our
COVID-19 cohort provides some supporting evidence of this phe-
nomenon. This group had a significantly higher number of circuit
changes due to oxygenator thrombosis and these oxygenator5
failures occurred despite therapeutic anticoagulation and even
occurred multiple times for some patients. In addition, data have
suggested endotheliopathy as a possible etiology of the observed
hypercoagulability associated with COVID-19, with evidence that
the virus can invade the endothelium leading to widespread
vascular damage that is not limited to the lung.28 Goshua et al.
correlated the degree of endotheliopathy with an increase in the
risk of critical illness and death.29 Another postulated hypotheses is
related to the severe inflammatory response detected in COVID-19
compared to other viral pneumonias. The significance of an exag-
gerated inflammatory milieu is unclear and may be less impactful
on mortality than coagulopathy.30,31 Further investigations into
possible genetic factors associated with severe COVID-19 infection
susceptibility may also bring further insights into the pathogen-
esis.32 In summary, these systemic manifestations of COVID-19
likely play a role in distinguishing it from influenza pneumonia.
Unfortunately, few studies exist that directly compare severe
ARDS in COVID-19 to influenza and the available data is equivocal.
Cobb et al. published a comparison of critically ill hospitalized
COVID-19 and influenza patients managed without ECMO that
demonstrated similar demographic differences between the two
cohorts and a comparable increase in mortality for COVID-19 pa-
tients with an adjusted relative risk of death of 2.13, similar to our
study.19 On the other hand, early data of hospitalized patients from
China showed a decrease in the adjusted risk of mortality for pa-
tients with COVID-19 compared to similarly ill patients with H1N1,
although this report came very early in the pandemic.18 Two
recently published small institutional studies comparing patients
placed on V-V ECMO for COVID-19 and influenza also reported
varying results. In contrast to our study, J€ackel et al. reported
similar cohorts from Germany in baseline characteristics and did
not find a significant mortality difference between those with
influenza and COVID-19, although patients in the COVID-19 group
were on ECMO significantly longer.20 A similar study from France
by Cousin et al. also showed that COVID-19 patients were cannu-
lated later in their clinical course than influenza patients but did
not show a higher mortality risk for COVID-19 patients.21
L.A. Raff, T.D. Reid, D. Johnson et al. The American Journal of Surgery xxx (xxxx) xxxThe potential causes of the significant mortality difference be-
tween influenza and COVID-19 patients at our center are likely
multi-factorial. The relative difference between our extensive
experience treating influenza patients compared with managing
patients with COVID-19 may be one factor. Recent data from the
United Kingdom and the United States has shown a decline in
COVID-19 associated mortality over time for hospitalized pa-
tients.33,34 This may reflect that treatment of COVID-19 has
improved as providers have gained more experience treating the
novel aspects of the virus along with the development of new
COVID-19 therapies. Over time, ECMO-related outcomes may also
improve for patients with severe COVID-19. On the other hand, our
group’s past experience with influenza also provided valuable les-
sons when facing the challenges of a new pandemic. Our expertise
with ECMO and influenza likely informed some aspects of ECMO
management for COVID-19, which may have improved outcomes
for some patients. We also acknowledge that our in-hospital mor-
tality for COVID-19 patients on ECMO is higher than that currently
reported by ELSO and several other single-center
studies.16,20,21,35,36 However, unlike many centers, we did not
impose strict absolute contraindications based on age or pre-ECMO
duration of mechanical ventilation when selecting COVID-19 pa-
tients appropriate for ECMO therapy. However, these variables
were significantly more common in the COVID-19 group and are
associated with worse outcomes.37,38 ECMO is an expensive and
limited resource even in ECMO centers, necessitating a thoughtful
patient selection approach. The patient selection process will only
become more difficult as the number of critically ill patients in-
creases. As we approach the winter months, potentially managing
both influenza and COVID-19 patients, we need more data to help
ECMO providers predict which patients are most likely to benefit
from V-V ECMO for severe ARDS associated with COVID-19 in order
to optimize the use of this valuable resource.
Our study is limited due to the retrospective and single insti-
tution methodology. The timeline for influenza patients stretched
over a long period of time but the primary clinician team remained
constant throughout the study period. Furthermore, it may be
underpowered to identify some significant differences between
patients with severe ARDS requiring ECMO for COVID-19 and
influenza. However, institutional experiences from high volume
centers remain vitally important. In addition, despite relatively
small numbers, we were able to identify important risk factors for
mortality and make meaningful comparisons between patients
with influenza and those with COVID-19.
Conclusion
In this study, we show an increased adjusted hazard for mor-
tality in patients with severe ARDS secondary to COVID-19 virus as
compared to influenza following V-V ECMO. Providers should
carefully weigh a number of patient factors such as age, medical
comorbidities, and the duration of illness when utilizing this scarce
resource in favor of influenza pneumonia. Further studies are
needed to define best practices of critical care management in
COVID-19 patients, including the use of V-V ECMO.
Author contributions
LR, JG, ER, TR, AC, AS, DJ collected data, analyzed data, wrote and
edited the manuscript.
Declaration of competing interest
None by any author.6
Acknowledgements
No funding was used for this project.References
1. Hardin C, Hibbert K. ECMO for severe ARDS. NEJM. 2018;378(21):2032.
2. Peek GJ, Clemens F, Elbourne D, et al. CESAR: conventional ventilatory support
vs extracorporeal membrane oxygenation for severe adult respiratory failure.
BMC Health Serv Res. 2006;6(1):1e13.
3. Karagiannidis C, Brodie D, Strassmann S, et al. Extracorporeal membrane
oxygenation: evolving epidemiology and mortality. Intensive Care Med.
2016;42(5):889e896.
4. Combes A, Hajage D, Capellier G, et al. Extracorporeal membrane oxygenation
for severe acute respiratory distress syndrome. NEJM. 2018;378(21):
1965e1975.
5. Thiagarajan RR, Barbaro RP, Rycus PT, et al. Extracorporeal life support orga-
nization registry international report 2016. Am Soc Artif Intern Organs J.
2017;63(1):60e67.
6. Davies AR, Jones D, Bailey M, et al. Extracorporeal membrane oxygenation for
2009 influenza A (H1N1) acute respiratory distress syndrome. J Am Med Assoc.
2009;302(17):1888e1895.
7. Buchner J, Mazzeffi M, Kon Z, et al. Single-center experience with venovenous
ECMO for influenza-related ARDS. J Cardiothorac Vasc Anesth. 2018;32(3):
1154e1159.
8. Zangrillo A, Biondi-Zoccai G, Landoni G, et al. Extracorporeal membrane
oxygenation (ECMO) in patients with H1N1 influenza infection: a systematic
review and meta-analysis including 8 studies and 266 patients receiving ECMO.
Crit Care. 2013;17(1):1e8.
9. Schmidt M, Bailey M, Sheldrake J, et al. Predicting survival after ECMO for se-
vere acute respiratory failure: the Respiratory ECMO Survival Prediction (RESP)
Score. Am J Respir Crit Care Med. 2014;189(11):1374e1382.
10. Maurice AMdS, Bridges BC, Rycus PT, et al. Global trends in ECMO use and
survival of patients with influenza associated illness. Pediatr Crit Care Med.
2016;17(9):876.
11. Sullivan SJ, Jacobson RM, Dowdle WR, et al., eds. H1N1 Influenza. Mayo Clinic
Proceedings. Elsevier; 2009, 2010.
12. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza
A (H1N1) infection in Canada. J Am Med Assoc. 2009;302(17):1872e1879.
13. Abaziou T, Delmas C, Vardon Bounes F, et al. Outcome of critically ill patients
with influenza infection: a retrospective study. Infect Dis Res Treat. 2020;13,
1178633720904081.
14. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients
with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospec-
tive, observational study. Lancet Respiratory Med. 2020 May;8(5):475e481.
https://doi.org/10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
15. Li X, Guo Z, Li B, et al. Extracorporeal membrane oxygenation for coronavirus
disease 2019 in Shanghai, China. Am Soc Artif Intern Organs J. 2020;66(5):475.
16. Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane
oxygenation support in COVID-19: an international cohort study of the
Extracorporeal Life Support Organization registry. Lancet. 2020;396(10257):
1071e1078.
17. Covid TC, Team R. Severe outcomes among patients with coronavirus disease
2019 (COVID-19)-United States, february 12-march 16, 2020. MMWR Morb
Mortal Wkly Rep. 2020;69(12):343e346.
18. Tang X, Du R, Wang R, et al. Comparison of hospitalized patients with acute
respiratory distress syndrome caused by covid-19 and H1N1. Chest. 2020
Jul;158(1):195e205. https://doi.org/10.1016/j.chest.2020.03.032.
19. Cobb NL, Sathe NA, Duan KI, et al. Comparison of clinical features and outcomes
in critically ill patients hospitalized with COVID-19 versus influenza. Annals Am
Thorac Soc. 2020 Nov 13. https://doi.org/10.1513/AnnalsATS.202007-805OC
(Epub ahead of print).
20. J€ackel M, Rilinger J, Lang CN, et al. Outcome of acute respiratory distress syn-
drome requiring extracorporeal membrane oxygenation in Covid-19 or
influenzaea single-center registry study. Artif Organs. 2020 Nov 14. https://
doi.org/10.1111/aor.13865.
21. Cousin N, Bourel C, Carpentier D, et al. SARS-CoV-2 versus influenza associated
acute respiratory distress syndrome requiring veno-venous extracorporeal
membrane oxygenation support. Am Soc Artif Intern Organs J. 2020 Oct 13.
https://doi.org/10.1097/MAT.0000000000001325.
22. Ho FK, Celis-Morales CA, Gray SR, et al. Modifiable and non-modifiable risk
factors for COVID-19, and comparison to risk factors for influenza and pneu-
monia: results from a UK Biobank prospective cohort study. BMJ Open.
2020;10(11), e040402.
23. Czernichow S, Beeker N, Rives-Lange C, et al. Obesity doubles mortality in
patients hospitalized for SARS-CoV-2 in Paris hospitals, France: a cohort study
on 5795 patients. Obesity. 2020 Dec;28(12):2282e2289. https://doi.org/
10.1002/oby.23014. Epub 2020 Nov 6.
24. Mancuso P. Obesity and respiratory infections: does excess adiposity weigh
down host defense? Pulm Pharmacol Therapeut. 2013;26(4):412e419.
25. Slutsky AS, Ranieri VM. Ventilator-induced lung injury. NEJM. 2013;369(22):
2126e2136.
26. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular
L.A. Raff, T.D. Reid, D. Johnson et al. The American Journal of Surgery xxx (xxxx) xxxendothelialitis, thrombosis, and angiogenesis in Covid-19. NEJM. 2020 Jul
9;383(2):120e128. https://doi.org/10.1056/NEJMoa2015432.
27. Middleton EA, He X-Y, Denorme F, et al. Neutrophil extracellular traps
contribute to immunothrombosis in COVID-19 acute respiratory distress syn-
drome. Blood. 2020;136(10):1169e1179.
28. Colmenero I, Santonja C, Alonso-Ria~no M, et al. SARS-CoV-2 endothelial
infection causes COVID-19 chilblains: histopathological, immunohistochemical
and ultrastructural study of seven paediatric cases. Br J Dermatol. 2020;183(4):
729e737.
29. Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated
coagulopathy: evidence from a single-centre, cross-sectional study. Lancet
Haematol. 2020;7(8):e575ee582.
30. Sinha P, Matthay MA, Calfee CS. Is a “cytokine storm” relevant to COVID-19?
JAMA Int Med. 2020;180(9):1152e1154.
31. Mangalmurti N, Hunter CA. Cytokine storms: understanding COVID-19. Im-
munity. 2020 Jul 14;53(1):19e25. https://doi.org/10.1016/
j.immuni.2020.06.017. Epub 2020 Jun 28.
32. Group SC-G. Genomewide association study of severe Covid-19 with respira-
tory failure. NEJM. 2020;383(16):1522e1534.
33. Asch DA, Sheils NE, Islam MN, et al. Variation in US hospital mortality rates for7
patients admitted with COVID-19 during the first 6 Months of the pandemic.
JAMA Intern Med. 2020 Dec 22, e208193. https://doi.org/10.1001/jamai-
nternmed.2020.8193. Epub ahead of print.
34. Dennis JM, McGovern AP, Vollmer SJ, Mateen BA. Improving survival of critical
care patients with coronavirus disease 2019 in England: a national cohort
study, March to June 2020. Critical Care Med. 2021 Feb;49(2):209.
35. Shaefi S, Brenner SK, Gupta S, et al. Extracorporeal membrane oxygenation in
patients with severe respiratory failure from COVID-19. Intensive Care Med.
2021 Feb 2:1e4.
36. Biancari F, Mariscalco G, Dalen M, et al. Six-month survival after extracorporeal
membrane oxygenation for severe COVID-19. J Cardiothorac Vasc Anesth. 2021
Jan 19;S1053-0770(21):00062e00068. https://doi.org/10.1053/
j.jvca.2021.01.027. Epub ahead of print.
37. Rajagopal K, Keller SP, Akkanti B, et al. Advanced pulmonary and cardiac
support of COVID-19 patients: emerging recommendations from ASAIOda
living working document. Circulation: Heart Fail. 2020;13(5), e007175.
38. Osho AA, Moonsamy P, Hibbert KA, et al. Veno-venous extracorporeal mem-
brane oxygenation for respiratory failure in COVID-19 patients: early experi-
ence from a major academic medical center in North America. Ann Surg. 2020
Aug;272(2):e75ee78.
